title: Pasireotide (SIGNIFOR) in acromegaly. After treatment failure: better than pegvisomant.
abstract: In a trial including 198 patients in whom several lines of treatments had failed, pasireotide normalised IGF-1 and GH levels and sometimes reduced the size of the pituitary adenoma, but often at a cost of developing diabetes.
mesh_terms: D000172:Acromegaly / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives*; D017211:Treatment Failure
chemical_list: D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; C517782:pasireotide; C406545:pegvisomant